Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Hematol Oncol Clin North Am. 2013 Apr 13;27(3):541–563. doi: 10.1016/j.hoc.2013.02.001

Figure 1. Evolution of the immune response relative to clinical manifestations of HIT.

Figure 1

12 patients with HIT and 36 seropositive non-HIT control patients were monitored for PF4/heparin antibodies, thrombocytopenia and thrombosis after orthopedic surgery. HIT patients are indicated by ■, and seropositive non-HIT controls by □. Time course of seroconversions are shown on the x-axis and OD levels between the patients with HIT and the seropositive non-HIT controls (P < 0.05 by nonpaired t test) are shown on the y-axis. At the top of the figure, summary data for 12 HIT patient profiles are shown for 4 key events (first day of antibody detection, beginning of HIT-related platelet count fall, platelet count fall ≥ 50%, and thrombotic event), summarized as median (small black squares within rectangles), interquartile range (open rectangles), and range (ends of thin black lines). Adapted from Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. The New England journal of medicine 1995;332:1330-5.with permission.